Compare · HUM vs TLSI
HUM vs TLSI
Side-by-side comparison of Humana Inc. (HUM) and TriSalus Life Sciences Inc. (TLSI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HUM and TLSI operate in Medical Specialities (Health Care), so they compete in similar markets.
- HUM is the larger of the two at $48.02B, about 182.3x TLSI ($263.5M).
- Over the past year, HUM is up 78.9% and TLSI is down 5.9% - HUM leads by 84.8 points.
- TLSI has been more active in the news (9 items in the past 4 weeks vs 3 for HUM).
- HUM has more recent analyst coverage (25 ratings vs 6 for TLSI).
- Company
- Humana Inc.
- TriSalus Life Sciences Inc.
- Price
- $400.21+3.63%
- $4.29-1.61%
- Market cap
- $48.02B
- $263.5M
- 1M return
- +8.37%
- +3.00%
- 1Y return
- +78.90%
- -5.92%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 3
- 9
- Recent ratings
- 25
- 6
Humana Inc.
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, predictive modeling and informatics services, and clinical care services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2020, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was incorporated in 1964 and is headquartered in Louisville, Kentucky.
Latest HUM
- Humana upgraded by Wells Fargo with a new price target
- SEC Form 4 filed by Director Hilzinger Kurt J
- The Humana Foundation Deepens Investment in Emotional Health, Announcing Over $12 Million in New Grants
- SEC Form 11-K filed by Humana Inc.
- SEC Form 11-K filed by Humana Inc.
- Humana Inc. to Release Second Quarter 2026 Results on July 29, 2026
- Humana Awarded Statewide Illinois HealthChoice Medicaid Contract, Expanding Access to Care Across the State
- Humana Announces Agreement to Divest Minority Interest in Gentiva
- Humana Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Humana completes $83 million Florida infrastructure investment to deepen coordinated patient care approach
Latest TLSI
- TriSalus Life Sciences to Host Second Quarter 2026 Financial Results Conference Call
- Amendment: SEC Form SCHEDULE 13G/A filed by TriSalus Life Sciences Inc.
- Chief Financial Officer Patience David covered exercise/tax liability with 14,650 shares, decreasing direct ownership by 5% to 261,107 units (SEC Form 4) (tax liability)
- CEO and President Szela Mary T was granted 3,990 shares, increasing direct ownership by 0.37% to 1,077,683 units (SEC Form 4)
- Szela Mary T increased direct ownership by 101% to 1,023,826 units (SEC Form 5)
- Chief Commercial Officer Marshak Richard was granted 561 shares, increasing direct ownership by 0.44% to 128,319 units (SEC Form 4)
- Marshak Richard increased direct ownership by 383% to 131,758 units (SEC Form 5)
- Chief Medical Officer Marshall Richard Henry was granted 60,000 shares, increasing direct ownership by 200% to 90,000 units (SEC Form 4)
- New insider Marshall Richard Henry claimed ownership of 30,000 shares (SEC Form 3)
- TriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver Cancer